Why GLP-1 weight loss pills could spark big pharma's next rally
The shift from injectable treatments to oral GLP-1 weight-loss pills is setting the stage for a major turning point across big pharma, led by the battle between Novo Nordisk and Eli Lilly. As adoption rates climb globally, this booming drug class could be poised to reshape healthcare earnings while sending ripple effects through the broader consumer economy.
Today's watchlist: Novo Nordisk, Judo Bank
Check out these stocks: www.moomoo.com/quote
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.